Growth hormone as a new treatment modality for short children with chronic renal failure

被引：8

作者：

Mehls, O

Haffner, D

Wuhl, E

Tonshoff, B

Schaefer, F

Heinrich, U

Bittner, K

Ehrich, JHH

Filler, G

Gellermann, J

Hampel, H

Bachmann, H

Ruder, H

Bonzel, KE

Scheller, B

Dippell, J

Zimmerhackl, LB

Kreuder, J

Rascher, W

MullerWiefel, DE

Misselwitz, J

Ronnefarth, B

Querfeld, U

Eichstadt, H

Greiner, C

Keller, E

Weber, HP

Heise, HR

Wiemann, D

Beetz, R

Sasse, D

Soergel, M

Pistor, K

Zlotkowski, A

Klare, B

Eife, R

KuwertzBroking, E

Wigger, M

Mix, M

Eicher, O

机构：

[1] Division of Pediatric Nephrology, University Children’s Hospital of Heidelberg

来源：

HORMONE RESEARCH | 1996年 / 46卷 / 4-5期

关键词：

chronic renal failure; dialysis; renal transplantation; growth failure; growth hormone;

D O I：

10.1159/000185028

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Recombinant human growth hormone (rhGH) has become a new treatment modality for short children with chronic renal failure (CRF) and after renal transplantation. The rationale for high-dose rhGH treatment is the insensitivity of the uremic organism to GH. As the insensitivity to GH is expressed more in end-stage renal failure than in earlier stages of CRF, patients on dialysis respond less to rhGH. In transplanted children, rhGH can counterbalance the growth-depressing effects of corticosteroids, In prepubertal children, rhGH improves the height standard deviation score by a mean of +2 within 5 years. The effect of rhGH treatment on final height remains to be studied.

引用

页码：230 / 235

页数：6

共 54 条

[1]

BANG P, 1993, ACTA ENDOCRINOL-COP, V128, P397

[2] EFFECTS OF GROWTH-HORMONE ADMINISTRATION IN PEDIATRIC RENAL-ALLOGRAFT RECIPIENTS [J].